---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-26-000028"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2026-08-04T20:03:26+00:00"
generated_at: "2026-08-04T20:04:22.594956+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Gilead Q2 2026 Revenue Up 10% to $7.8B; Diluted Loss Per Share $(8.45) on $11.2B IPR&D Charges

## Summary
- Total Q2 2026 revenues increased 10% to $7.8 billion compared to Q2 2025.
- Product sales excluding Veklury increased 10% to $7.6 billion, driven by HIV portfolio, Trodelvy, and Livdelzi.
- Diluted loss per share was $(8.45) due to $11.2 billion in acquired IPR&D expenses from Arcellx, Tubulis, and Ouro Medicines acquisitions.
- Biktarvy sales increased 7% to $3.8 billion; Descovy sales up 48% to $967 million.
- Gilead updated 2026 guidance: product sales ex-Veklury now $29.8B-$30.1B, up from prior $29.4B-$29.8B.

## SEC filing metadata
- accession: 0000882095-26-000028
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2026-08-04T20:03:26+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/0000882095-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/gild-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-26-000028
- JSON: https://secwatch.observer/filing/0000882095-26-000028.json
- Plain text: https://secwatch.observer/filing/0000882095-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.